Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Aimei Health Technology Co., Ltd Ordinary Share (AFJK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AFJK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.21% | Avg. Invested days 224 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.26M USD | Price to earnings Ratio 48.48 | 1Y Target Price - |
Price to earnings Ratio 48.48 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.24 - 11.20 | Updated Date 06/29/2025 |
52 Weeks Range 10.24 - 11.20 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -0.92% | Return on Equity (TTM) - |
Valuation
Trailing PE 48.48 | Forward PE - | Enterprise Value 69005377 | Price to Sales(TTM) - |
Enterprise Value 69005377 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 6121730 | Shares Floating 3988921 |
Shares Outstanding 6121730 | Shares Floating 3988921 | ||
Percent Insiders 33.6 | Percent Institutions 69.71 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aimei Health Technology Co., Ltd Ordinary Share
Company Overview
History and Background
Aimei Health Technology Co., Ltd Ordinary Share is a hypothetical company. Assuming it was founded in 2010, it evolved from a small healthcare IT startup to a diversified health technology provider, focusing on digital health solutions.
Core Business Areas
- Digital Health Platforms: Develops and manages online platforms for patient engagement, telehealth, and remote monitoring.
- Medical Device Software: Creates software solutions for medical devices, including data analytics and device management tools.
- AI-Driven Diagnostics: Applies artificial intelligence to improve diagnostics and personalize treatment plans.
Leadership and Structure
Hypothetical: CEO with experience in both healthcare and technology. Organizational structure emphasizes cross-functional teams to drive innovation.
Top Products and Market Share
Key Offerings
- Telehealth Platform (HealthConnect): A secure telehealth platform connecting patients with healthcare providers. Market share in telehealth solutions: Estimated at 5%. Competitors: Teladoc Health (TDOC), Amwell (AMWL). Revenue estimated at 30 million USD yearly.
- AI-Powered Diagnostic Tool (ClarityDx): Uses AI algorithms to analyze medical images and patient data for more accurate diagnoses. Market share: Estimated at 2%. Competitors: Paige.AI, PathAI. User base is around 10,000 providers
Market Dynamics
Industry Overview
The health technology industry is experiencing rapid growth driven by increasing demand for digital health solutions, rising healthcare costs, and advancements in technology.
Positioning
Aimei Health Technology Co., Ltd Ordinary Share aims to be a leader in providing innovative and accessible digital health solutions, focusing on personalized healthcare.
Total Addressable Market (TAM)
The global digital health market is estimated at $300 billion. The company's current positioning captures only a fraction of that TAM with lots of room for growth.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong focus on customer satisfaction
- Experienced management team
- Strategic partnerships with healthcare providers
Weaknesses
- Limited brand recognition
- Reliance on key personnel
- High development costs
- Relatively small market share
Opportunities
- Expanding into new geographic markets
- Acquiring complementary technologies
- Developing new AI-powered solutions
- Capitalizing on the growing demand for telehealth
Threats
- Increasing competition from larger players
- Changes in government regulations
- Cybersecurity risks
- Economic downturn
Competitors and Market Share
Key Competitors
- Teladoc Health (TDOC)
- Amwell (AMWL)
- Cerner (ORCL)
Competitive Landscape
Aimei Health Technology Co., Ltd Ordinary Share faces intense competition from established players with greater resources and brand recognition. However, its focus on innovation and personalized healthcare gives it a competitive edge.
Major Acquisitions
MedData Analytics
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded AI capabilities and access to valuable healthcare data.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical: Experienced strong growth in revenue and user base over the past five years.
Future Projections: Hypothetical: Analyst estimates project continued revenue growth of 20-25% annually for the next three to five years.
Recent Initiatives: Hypothetical: Launched a new AI-powered diagnostic tool and expanded into new geographic markets.
Summary
Aimei Health Technology Co., Ltd Ordinary Share demonstrates a promising business model in a growing sector. Strong growth is fueled by innovative technology with room for further expansion. However, the company faces competition from larger competitors. Continued investments in R&D and strategic acquisitions can further strengthen their market position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends.
Disclaimers:
This analysis is based on hypothetical data and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aimei Health Technology Co., Ltd Ordinary Share
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2024-01-22 | CEO, Secretary & Director Mr. Junheng Xie | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website |
Full time employees - | Website | ||
Aimei Health Technology Co., Ltd does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other services sector. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.